![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HGF |
Gene summary for HGF |
![]() |
Gene information | Species | Human | Gene symbol | HGF | Gene ID | 3082 |
Gene name | hepatocyte growth factor | |
Gene Alias | DFNB39 | |
Cytomap | 7q21.11 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P14210 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3082 | HGF | ATC12 | Human | Thyroid | ATC | 1.06e-50 | 1.26e+00 | 0.34 |
3082 | HGF | ATC13 | Human | Thyroid | ATC | 2.48e-11 | 2.29e-01 | 0.34 |
3082 | HGF | ATC4 | Human | Thyroid | ATC | 5.56e-59 | 1.47e+00 | 0.34 |
3082 | HGF | ATC5 | Human | Thyroid | ATC | 2.61e-10 | 2.60e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
GO:001056334 | Thyroid | ATC | negative regulation of phosphorus metabolic process | 234/6293 | 442/18723 | 2.30e-17 | 2.31e-15 | 234 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:004593634 | Thyroid | ATC | negative regulation of phosphate metabolic process | 233/6293 | 441/18723 | 3.68e-17 | 3.47e-15 | 233 |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:000030234 | Thyroid | ATC | response to reactive oxygen species | 128/6293 | 222/18723 | 1.38e-13 | 7.00e-12 | 128 |
GO:004254233 | Thyroid | ATC | response to hydrogen peroxide | 92/6293 | 146/18723 | 3.12e-13 | 1.46e-11 | 92 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:2001236210 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway | 89/6293 | 151/18723 | 1.43e-10 | 4.40e-09 | 89 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HGF | MET | HGF_MET | HGF | Breast | Healthy |
HGF | MET | HGF_MET | HGF | Cervix | Precancer |
HGF | MET | HGF_MET | HGF | Endometrium | EEC |
HGF | MET | HGF_MET | HGF | Liver | HCC |
HGF | MET | HGF_MET | HGF | Liver | Healthy |
HGF | MET | HGF_MET | HGF | Liver | Precancer |
HGF | MET | HGF_MET | HGF | Lung | IAC |
HGF | MET | HGF_MET | HGF | Prostate | BPH |
HGF | MET | HGF_MET | HGF | Prostate | Healthy |
HGF | MET | HGF_MET | HGF | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HGF | SNV | Missense_Mutation | novel | c.1631A>T | p.Tyr544Phe | p.Y544F | P14210 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-CV-5432-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | c.297N>A | p.Phe99Leu | p.F99L | P14210 | protein_coding | tolerated(1) | benign(0.006) | TCGA-CV-7245-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | novel | c.709C>T | p.His237Tyr | p.H237Y | P14210 | protein_coding | tolerated(0.14) | benign(0.325) | TCGA-CV-7406-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | c.559N>T | p.Pro187Ser | p.P187S | P14210 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CV-7429-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
HGF | SNV | Missense_Mutation | novel | c.1456T>A | p.Ser486Thr | p.S486T | P14210 | protein_coding | tolerated(0.36) | benign(0.005) | TCGA-UF-A71A-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
HGF | SNV | Missense_Mutation | c.925N>A | p.Gln309Lys | p.Q309K | P14210 | protein_coding | tolerated(0.68) | probably_damaging(0.991) | TCGA-EJ-5515-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.1391G>A | p.Cys464Tyr | p.C464Y | P14210 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G9-6371-01 | Prostate | prostate adenocarcinoma | Male | <65 | 6 | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | novel | c.869A>G | p.Asp290Gly | p.D290G | P14210 | protein_coding | tolerated(0.38) | benign(0) | TCGA-YL-A8SH-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | c.1427N>T | p.Thr476Ile | p.T476I | P14210 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.1070N>A | p.Pro357Gln | p.P357Q | P14210 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-8297-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | STI571 | IMATINIB MESYLATE | 11439348 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | THALIDOMIDE | THALIDOMIDE | 15939924 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | ASPIRIN | ASPIRIN | 11981761 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | VM-202 | |||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | Ficlatuzumab | FICLATUZUMAB | ||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | PROTEOLYTIC ENZYMES | 9502079 | ||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | antibody | RILOTUMUMAB | RILOTUMUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | RESVERATROL | RESVERATROL | 15672869 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | TAK-701 | |||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | FICLATUZUMAB | FICLATUZUMAB |
Page: 1 2 3 |